Chart and TA, page-56

I've never seen one of those algorithms website able to accurately predict any Biotech stock share price or trend.

The key for researching Biotechs especially smaller cap ones is what is the Total Addressable Markets for each indication and potential of the current drug clinical trials to get there.

So best is to start with ASX announcements and CEO Investor Presentations to see what the company is trying to do to break down the science and company trajectory.
eg. Are they trying something completely novel and new, or is it an improvement on existing tech, where more easily comparable.

PXS is a bit of a rarity in that it actually has 2 approved and marketed drugs, but as they are manufactured and marketed locally the cost bases is a lot higher than if this was outsourced, but there has been some great developments in licencing out the expense of marketing and selling these drugs which will significantly reduce their current cash burn rate.

Today's announcement should have a meaningful impact to the Q3 quarterly report figures.